Schott Pharma AG KGaASHTPY -42.88%64 Gross Margin % is 30.30% as of Mar. 2026, which is 12% below its 10-year median of 34.29. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 76.77% on this metric.
SHTPY's Gross Margin % is ranked worse than 76.77% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs SHTPY: 32.96
Schott Pharma AG KGaA had a gross margin of 30.30% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Schott Pharma AG KGaA was -0.30% per year.
Schott Pharma AG KGaA (OTCPK:SHTPY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Schott Pharma AG KGaA had a gross margin of 30.30% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Schott Pharma AG KGaA Gross Margin % Related Terms
Schott Pharma AG KGaA Gross Margin % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Schott Pharma AG KGaA (SHTPY) has a Gross Margin % of 30.30% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Schott Pharma AG KGaA and its competitors. This is 12% below median its historical median of 34.29. Over the past decade, Schott Pharma AG KGaA's Gross Margin % has ranged from 32.96 to 36.10. According to the industry distribution chart, Schott Pharma AG KGaA ranks #618 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is Schott Pharma AG KGaA's Gross Margin % too high?
Schott Pharma AG KGaA's current Gross Margin % of 30.30% is 12% below median its 10-year median of 34.29. Over the past 10 years, this metric has ranged from a low of 32.96 to a high of 36.10. The Medical Devices & Instruments industry median Gross Margin % is 51.94. Schott Pharma AG KGaA's value of 30.30% is 41.7% below this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #618 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #618 out of 805 companies for Gross Margin %. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median Gross Margin % is 51.94. Schott Pharma AG KGaA's value of 30.30% is 41.7% below this benchmark. Historically, Schott Pharma AG KGaA's own Gross Margin % has ranged from 32.96 to 36.10 over the past decade. While the company's 10-year median is 34.29 vs. the industry median of 51.94, Schott Pharma AG KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Gross Margin % of 30.30% is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Gross Margin % is 30.30%, which is 12% below median its own 10-year median of 34.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Gross Margin % of 30.30%. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Gross Margin % is 30.30%, which is 12% below median its 10-year median of 34.29 and 41.7% below the Medical Devices & Instruments industry median of 51.94. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Gross Margin % is 30.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
Gross Margin %: 30.30% (12% below median its 10-year median of 34.29)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 41.7% below the Medical Devices & Instruments median (#618 of 805)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
